标题
Secondary malignancies among mantle cell lymphoma patients
作者
关键词
-
出版物
EUROPEAN JOURNAL OF CANCER
Volume -, Issue -, Pages 113403
出版商
Elsevier BV
发表日期
2023-10-29
DOI
10.1016/j.ejca.2023.113403
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Long term follow-up of Rituximab plus Bendamustine and Cytarabine (R-BAC) in elderly patients with newly diagnosed MCL
- (2023) Maria Chiara Tisi et al. Blood Advances
- Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study
- (2022) Joel Kristinn Joelsson et al. Blood Advances
- Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
- (2022) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases
- (2022) Youxi Yu et al. Cell and Bioscience
- Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden
- (2021) Jonas F Ludvigsson et al. Clinical Epidemiology
- Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial
- (2021) Vincent Ribrag et al. BLOOD
- Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database
- (2020) Jin Seok Kim et al. Cancer Research and Treatment
- Second primary cancers in non‐Hodgkin lymphoma: Family history and survival
- (2019) Subhayan Chattopadhyay et al. INTERNATIONAL JOURNAL OF CANCER
- Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial
- (2019) Martin Dreyling et al. BLOOD
- Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population‐based cohort study
- (2019) Ingrid Glimelius et al. BRITISH JOURNAL OF HAEMATOLOGY
- A systematic comparison of recurrent event models for application to composite endpoints
- (2018) Ann-Kathrin Ozga et al. BMC Medical Research Methodology
- Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
- (2018) Wolfgang Hiddemann et al. JOURNAL OF CLINICAL ONCOLOGY
- Frontline Treatment for Older Patients with Mantle Cell Lymphoma
- (2018) Haige Ye et al. ONCOLOGIST
- Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow-up from a pooled analysis
- (2018) Simon Rule et al. HAEMATOLOGICA
- Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma
- (2017) Apurvasena Parikh et al. LEUKEMIA & LYMPHOMA
- Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
- (2016) A. Albertsson-Lindblad et al. BLOOD
- Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis
- (2015) I. Fleury et al. ANNALS OF ONCOLOGY
- Modelling recurrent events: a tutorial for analysis in epidemiology
- (2014) Leila DAF Amorim et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
- (2013) Lois B. Travis et al. Nature Reviews Clinical Oncology
- Dose Dependent Effects on Cell Cycle Checkpoints and DNA Repair by Bendamustine
- (2012) Neil Beeharry et al. PLoS One
- Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry
- (2011) Anna Abrahamsson et al. LEUKEMIA & LYMPHOMA
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started